X4 PHARMACEUTICALS IN

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022

08 мар 2022 07:00:03 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at March Investor Conferences

03 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 фев 2022 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

19 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 янв 2022 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential for Mavorixafor in the Treatment of Primary Immunodeficiencies

13 дек 2021 07:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia

11 дек 2021 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

02 дек 2021 05:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 дек 2021 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Stifel’s Virtual Healthcare Conference

10 ноя 2021 07:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Scientific Data; Company Reports Third Quarter Financial Results

04 ноя 2021 08:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ноя 2021 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 4, 2021

25 окт 2021 07:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial

19 окт 2021 07:00:02 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Completes Enrollment in Phase 3 Mavorixafor Trial in Patients with WHIM Syndrome

04 окт 2021 07:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 окт 2021 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Participate in Upcoming Investor Conferences

15 сен 2021 15:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Promotes Mary DiBiase, Ph.D. to Chief Operating Officer

08 сен 2021 07:00:04 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 сен 2021 15:01:00 Источник Nasdaq GlobeNewswire